Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Tinkers With Readmissions Policy, Other Quality Initiatives

This article was originally published in The Gray Sheet

Executive Summary

The agency plans to be more selective about which hospital readmissions count toward a potential payment reduction in fiscal year 2014, according to its inpatient payment proposal. CMS also proposes hip and knee replacements as a new category of hospital admission to be included in the readmissions reduction program.

You may also be interested in...

Boston Scientific Thinks Big In Heart Failure Risk-Share Plan

Value-based care and leveraging digital health and analytics are now viewed as the all-important ingredients in sustainable health care delivery. With that in mind, Boston Scientific and global professional services company Accenture recently joined forces in a total-cost-of-care heart failure project that is rewarded on patient outcomes.

Merck’s “Beyond The Pill” Bet, Vree Health, Goes Commercial

Vree Health, one of the independent subsidiaries Merck is fostering through its innovation ventures initiative, is moving into commercial phase, as it builds a business model that focuses on helping providers meet key goals of health care reform: higher quality and more cost-effective patient care.

CMS Updates Medicare Readmissions Policy, Other Quality Initiatives

The agency finalized updates to the readmissions program and to its value-based purchasing program in its final inpatient prospective payment system rule, which takes effect October 1.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts